Navigation Links
Natrix Separations Introduces New Leadership Team
Date:10/28/2011

BURLINGTON, Ontario, Oct. 28, 2011 /PRNewswire/ -- Natrix Separations, Inc. announced today new members of its leadership team, including John A. Chickosky as President & Chief Executive Officer and Molly S. McGlaughlin as Vice President of Business Development. Chickosky has been a member of the Natrix Board of Directors since mid-2010, and will continue to hold a board seat. McGlaughlin joined Natrix in June 2011.

C. Howie Honeyman, Ph.D. will continue as Senior Vice President, Research, Product Development & Applications and Robert Beveridge will remain as Chief Financial Officer.

The management team announcements coincide with a new round of investment from the existing slate of investors and a focused product development effort that is being conducted in close collaboration with biopharmaceutical industry leaders. The company is currently exploring additional collaboration partnerships to support this strategy.

Natrix Board Chairman Jim Iuliano commented, "John has been instrumental in assessing our technology and shaping our business strategy as a member of the board, and we are thrilled to have him leading the company during this exciting new phase of its development. He is widely respected among biopharm industry leaders and has demonstrated a deft hand in commercializing new technologies in this space."

Chickosky added, "Natrix's patented advective high-capacity chromatography technology has been well-received by the industry, and we are confident that it will deliver a step-change improvement in the way downstream processing is handled. We now have the right team and a focused plan to swiftly deliver the promise of Natrix's core technology to customers who need it to meet the challenges of a rapidly changing bioproduction environment."

Most recently, Chickosky was Chief Commercial Officer and President of the BioSystems Division of Xcellerex, Inc., where he led the development and execution of the company's commercial strategy. He brings more than 20 years of senior management experience with life science technology companies, including senior positions at Kendro Laboratory Products (now part of ThermoFisher), CARR Separations, and Sepracor, Inc. John holds a Bachelor of Science degree in Electrical Engineering and Computer Science from Santa Clara University and an MBA from St. Mary's College (California).

As Vice President of Business Development, Molly McGlaughlin is responsible for all commercial development and marketing for the company. Molly brings to Natrix more than 20 years of senior level biotechnology business development and marketing experience, most recently at Cytovance Biologics where she was Vice President of Sales and Business Development. Previously, she held commercial positions with leading life sciences companies including Avecia Biotechnology, Patheon and Tyco Healthcare. Molly is also a long-time member of the U.S. Army Reserves, where she is currently a Battalion Commander. She holds a B.S. in Biology from Norwich University, an M.eD. from the University of Massachusetts, Boston, and is a Doctoral candidate in the school of Business and Technology at Capella University concentrating on M&A in the Biotechnology sector.

ABOUT NATRIX SEPARATIONS Natrix Separations is commercializing a new downstream bioprocessing technology based on its patented advective chromatography platform. Natrix technology combines the superior binding capacity of conventional resin-based column chromatography with the high throughput of membrane chromatography. This performance enables a new level of flexibility in downstream processing, eliminating the reliance on fixed, capital-intensive glass or stainless chromatography columns while also reducing buffer and other consumables costs by as much as 80%. Natrix technology is packaged in a single-use format, eliminating the cleaning, sanitization, storage, and validation burdens of conventional approaches. This format speeds facility turnaround and makes complete single-use biomanufacturing operation feasible and practical.

Natrix is currently exploring collaboration programs with leading biopharmaceutical organizations to advance the commercialization of its technology.

For more information please visit www.natrixseparations.com.CONTACT:Molly McGlaughlin Natrix Separations 617-548-7927 mcglaughlin@natrixseparations.com
'/>"/>

SOURCE Natrix Separations, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Supelco(R) Introduces Breakthrough in Bioseparations Performance -- Ascentis(R) Express ES-C18 HPLC Columns
2. Myelin Removal Beads: Premium Efficiency for Neural Cell Separations and Antibody Stainings
3. Ventana Medical Systems, Inc. Introduces Groundbreaking Laboratory Workflow Integration
4. Molecular Devices, LLC Introduces SoftMax Pro® 6 Microplate Data Acquisition and Analysis Software With Powerful New Data Analysis and Reporting Features
5. SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line
6. Olympus Introduces Worlds First Autoclavable 5mm HD Deflectable Videolaparoscope
7. Top Plastic Surgeon Introduces Worlds First VECTRA XT 3D Imaging Solution
8. Invuity Introduces Advanced Illuminated Surgical System for Breast Procedures
9. Colorcon, Inc. Introduces Opadry® 200 Optimized Performance Film Coatings
10. Quest Introduces Its Next Generation AlphaView 4MP Medical LCD
11. Honeywell Introduces New Ultra-High Barrier Film for Pharmaceutical Packaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... DUBLIN , May 4, 2016 ... the "Global Cancer Stem Cell Therapy Market Outlook ... (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has ... therapeutics are expected to be developed in coming years. ... these techniques. Cancer stem cell therapies are also expected ...
(Date:5/3/2016)... , May 3, 2016  As a teenager, ... contracted rheumatic fever, which damaged his heart. He continued ... But by June 2013, Shepherd,s heart was giving out ... death. On June 20, 2013, the Mesa, ... Artificial Heart (TAH-t). Like a heart transplant, the SynCardia ...
(Date:5/3/2016)... , May 3, 2016   BIOTRONIK , ... today announced Food and Drug Administration (FDA) approval ... that provides heart failure patients with access to ... also have remote monitoring with daily automatic transmission ... heart rate in response to physiological demands. ...
Breaking Medicine Technology:
(Date:5/4/2016)... WA (PRWEB) , ... May ... ... a full service insurance provider serving families of Camas and Vancouver, WA, ... current campaign fundraises for the National Breast Cancer Foundation and their Mammography ...
(Date:5/4/2016)... ... May 04, 2016 , ... The RIDER Institute announces an ... DRACO broad-spectrum antiviral therapeutics. DRACOs have proven effective against all 18 viruses tested ... at http://igg.me/at/EndTheVirus and runs for 60 days, we are raising new ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nike Rugby Camp's success is due in ... Willis, founder of Elite Rugby Camps and current Nike Camp director, has offered an ... 2009. , “I’m excited for our eighth summer here in San Diego,” says ...
(Date:5/4/2016)... ... May 04, 2016 , ... All-Star ... created to assist the people of their local community. The agency pledges to ... community leaders. Their hope is to bring awareness to important local causes with ...
(Date:5/4/2016)... CA (PRWEB) , ... May 04, 2016 , ... Dr. ... offering wisdom tooth removal surgery at their office. Wisdom tooth removal, a common dental ... not always problematic, they often are improperly erupted, resulting in risks of complications. By ...
Breaking Medicine News(10 mins):